Clinical Trials in the EU / 2025-523261-25-00
Authorised, not yet recruiting
Phase II
A phase 2, single arm, open label, study on the safety and feasibility of Liver Isolated Oxaliplatin (LIOX) delivered via arterial access device for treatment of liver metastasis in colorectal cancer patients
2025-523261-25-00 · tracked via the Priya Life Science EU tracker
Condition studied
colorectal cancer
Investigational medicinal product(s)
Oxaliplatin Accord Healthcare 5 mg/ml concentraat voor oplossing voor infusie
Every trial of Oxaliplatin across our registers →
Eligibility
Primary endpoint
Incidence of adverse events
Endpoint detail
Liver Disease Control Rate
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2025-523261-25-00 on CTIS ↗ ← All trials in the EU